市場調査レポート

商品コード

1566183

特発性肺線維症の市場規模、シェア、成長分析、薬剤タイプ別、作用機序別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Idiopathic Pulmonary Fibrosis Market Size, Share, Growth Analysis, By Drug Type, By Mode of Action, By End User, By Region - Industry Forecast 2024-2031

出版日: 2024年10月03日 | 発行: SkyQuest

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 804,222円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 940,788円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,077,354円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=151.74円

全表示
概要
目次

概要

サンプル依頼リストに入れる

特発性肺線維症の世界市場規模は、2022年に35億米ドルと評価され、予測期間（2024-2031年）のCAGRは6.98%で、2023年の40億2,000万米ドルから2031年には108億米ドルに成長する見通しです。

世界の特発性肺線維症（IPF）市場は、進行性の肺組織の瘢痕化と機能障害を特徴とするこの深刻な肺疾患の罹患率の上昇に牽引され、著しい成長を遂げています。この市場拡大は、早期発見を強化し、より良い疾患管理を可能にする診断技術の進歩に加え、タイムリーな介入の必要性に対するヘルスケア専門家や患者の意識の高まりによるところが大きいです。製薬企業や研究者が抗線維化剤、免疫抑制剤、標的治療薬などの革新的な治療法の開発に注力する中、患者の転帰やQOLは顕著に改善されています。それにもかかわらず、治療費の高騰、特定の地域における治療法へのアクセスの制限、IPFの複雑性を解明するための継続的な調査の必要性などの課題は依然として残っています。さらに、米国IPF市場は今後も持続的なCAGRを維持すると予想されており、業界の発展、新たな研究成果、規制の最新情報を継続的にモニタリングする必要性が浮き彫りになっています。この洞察は、IPF市場における成長と革新の可能性を強調する一方で、患者のニーズを十分に満たし、新たな治療法の恩恵を活用するために対処すべき障害も認識しています。

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2023年）
主な市場企業が採用した戦略
市場における最近の活動
主要企業の市場シェア（2023年）

主要企業プロファイル

United Therapeutics Corporation
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Cipla Inc.
F. Hoffmann-La Roche Ltd
FibroGen Inc.
MediciNova Inc.
Jubilant Pharma Limited（Jubilant Cadista Limited）
Merck & Co. Inc.
Horizon Therapeutics Inc.
Avalyn Pharma Inc.
AstraZeneca
Novartis AG
GlaxoSmithKline plc
Genentech, Inc.
Biogen Inc.
Pfizer Inc.
AbbVie Inc.
Bayer AG
Amgen Inc.

Product Code: SQMIG35H2223

Global Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.50 billion in 2022 and is poised to grow from USD 4.02 billion in 2023 to USD 10.80 billion by 2031, growing at a CAGR of 6.98% during the forecast period (2024-2031).

The global Idiopathic Pulmonary Fibrosis (IPF) market is experiencing significant growth, driven by the rising incidence of this serious lung condition characterized by progressive lung tissue scarring and functional impairment. This expansion is largely attributed to advancements in diagnostic technologies that enhance early detection and enable better disease management, alongside increased awareness among healthcare professionals and patients for the need for timely intervention. As pharmaceutical companies and researchers focus on developing innovative treatment modalities-such as antifibrotic agents, immunosuppressants, and targeted therapies-patient outcomes and quality of life are notably improving. Nonetheless, challenges such as high treatment costs, restricted access to therapies in certain areas, and the necessity for ongoing research to unravel the complexities of IPF persist. Furthermore, the U.S. IPF market is expected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming years, highlighting the need for continuous monitoring of industry developments, new research findings, and regulatory updates. This insight emphasizes the potential for growth and innovation within the IPF market, while also acknowledging the obstacles that must be addressed to fully meet patient needs and harness the benefits of emerging therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Idiopathic Pulmonary Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Idiopathic Pulmonary Fibrosis Market Segmental Analysis

Global Idiopathic Pulmonary Fibrosis Market is segmented on the basis Global Idiopathic Pulmonary Fibrosis Market is segmented by Drug Type, Mode of Action, End User and Region. Based on Drug Type, the market is segmented into Nintedanib, Pirfenidone, Other Drug Types. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action. Based on End User, the market is segmented into Hospitals and Clinics, Pharmacies, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Idiopathic Pulmonary Fibrosis Market

The Global Idiopathic Pulmonary Fibrosis (IPF) market is significantly propelled by relentless advancements in medical research and drug development aimed at unraveling the complex biology of IPF. This progress has led to the introduction of groundbreaking therapies, exemplified by antifibrotic agents such as Nintedanib and Pirfenidone, which have revolutionized treatment paradigms. These innovative options not only enhance survival rates but also markedly improve patients' quality of life, fueling patient demand and clinical adoption. As ongoing research continues to unveil new targets and treatment modalities, the market is poised for substantial growth, driven by a reinforced commitment to tackling this debilitating condition.

Restraints in the Global Idiopathic Pulmonary Fibrosis Market

One significant restraint in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the prohibitive cost of treatment options. Medications like Nintedanib and Pirfenidone, while effective, are priced at a premium, limiting accessibility for patients, particularly in lower-income regions. This financial burden can deter patients from pursuing necessary therapies, resulting in diminished adherence to treatment regimens and compromised disease management. Furthermore, the escalating treatment costs can strain healthcare systems, raising concerns about disparities in access to effective care for all IPF patients, thereby hindering market growth and sustainability in various global territories.

Market Trends of the Global Idiopathic Pulmonary Fibrosis Market

A prominent trend in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the growing emphasis on developing targeted therapies. Pharmaceutical companies and research institutions are directing resources toward innovative treatment modalities that specifically address the underlying mechanisms of IPF, offering a more personalized approach to patient care. This focus not only aims to enhance treatment efficacy but also seeks to mitigate side effects commonly associated with traditional therapies. As a result, targeted therapies are anticipated to revolutionize disease management, improving patient outcomes through tailored interventions. This trend signifies a paradigm shift towards precision medicine in the IPF landscape, reflecting the evolving needs of patients and healthcare systems worldwide.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Pipeline Analysis
Patent Analysis

Idiopathic Pulmonary Fibrosis Market, By Drug Type

Market Overview
Nintedanib
Pirfenidone
Other Drug Types

Idiopathic Pulmonary Fibrosis Market, By Mode of Action

Market Overview
Antifibrotic Agents
Tyrosine Kinase Inhibitors
Other Modes of Action

Idiopathic Pulmonary Fibrosis Market, By End User

Market Overview
Hospitals and Clinics
Pharmacies
Other End Users

Idiopathic Pulmonary Fibrosis Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

United Therapeutics Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FibroGen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediciNova Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Pharma Limited (Jubilant Cadista Limited)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horizon Therapeutics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avalyn Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

特発性肺線維症の市場規模、シェア、成長分析、薬剤タイプ別、作用機序別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

Idiopathic Pulmonary Fibrosis Market Size, Share, Growth Analysis, By Drug Type, By Mode of Action, By End User, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

特発性肺線維症市場：薬剤タイプ別

特発性肺線維症市場：作用機序別

特発性肺線維症市場：エンドユーザー別

特発性肺線維症市場規模：地域別